We are live on
!
Find out more
VP
venBio Partners Portfolio holdings
AUM
$281M
1-Year Est. Return
261.03%
This Fund
S&P 500
This Quarter
Est. Return
-29.19%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$555M
AUM Growth
-$449M
(-45%)
Cap. Flow
+$71M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
2
Closed
1
Top Buys
| 1 |
VTYX
Ventyx Biosciences
VTYX
|
+$95M |
Top Sells
| 1 |
Harmony Biosciences
HRMY
|
+$12.9M |
| 2 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
+$10.5M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$646K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$262M
| $208M | 37.55% |
9,699,925
| – | – |
|
|
2
Harmony Biosciences
HRMY
$1.94B
| $117M | 21.05% |
2,740,411
-322,783
| -11% | -$12.9M |
|
|
VTYX
3
DELISTED
Ventyx Biosciences
VTYX
| $99.5M | 17.93% |
+5,011,536
| New | +$95M |
|
|
AKRO
4
DELISTED
Akero Therapeutics
AKRO
| $45.9M | 8.28% |
2,171,664
-29,114
| -1% | -$646K |
|
5
Pharvaris
PHVS
$2.4B
| $33.1M | 5.97% |
2,303,310
| – | – |
|
|
IMPL
6
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $23.8M | 4.29% |
2,759,791
| – | – |
|
|
ELEV
7
DELISTED
Elevation Oncology
ELEV
| $15.7M | 2.83% |
2,608,167
| – | – |
|
|
CMPI
8
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $10.5M | 1.9% |
3,673,374
| – | – |
|
|
VRNA
9
DELISTED
Verona Pharma
VRNA
| $1.09M | 0.2% |
161,897
| – | – |
|
|
MTCR
10
DELISTED
Metacrine, Inc. Common Stock
MTCR
| – | – |
-3,059,123
| Closed | -$10.5M |
|
Similar funds
OCWP
FFP
BDA
PHC
SA
ACC
NRCM
IP